Gustavo Barcelos Barra

Dr. Gustavo Barcelos Barra

Sabin Medicina Diagnóstica
+1
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ADAdrian Daly
Adrian Daly
MTMaria A. Tichomirowa
Maria A. Tichomirowa
PPPatrick Petrossians
Patrick Petrossians
EHElina Heliövaara
Elina Heliövaara
MJMarie-Lise Jaffrain-Rea
Marie-Lise Jaffrain-Rea
ABAlbert Beckers
Albert Beckers
Context:AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. Design: This study was an international, multicenter, retrospective case collection/database analysis. Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. Conclusions:AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility.

30 August 2007 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
ALAdriana Lofrano-Porto
Adriana Lofrano-Porto
Gustavo Barcelos BarraGustavo Barcelos Barra
Gustavo Barcelos Barra
LGLeonardo Abdala Giacomini
Leonardo Abdala Giacomini
PNPaula Pires Nascimento
Paula Pires Nascimento
ALAna Claudia Latronico
Ana Claudia Latronico
DADenis Reis de Assis
Denis Reis de Assis
Selective luteinizing hormone deficiency due to mutations in the luteinizing hormone beta-subunit gene (LHB) is a rare cause of hypogonadism. We describe the clinical features of a consanguineous family in which three siblings, two men and one woman, had hypogonadism related to isolated luteinizing hormone deficiency. These subjects have a newly discovered homozygous mutation of a 5′ splice site in LHB: IVS2+1G→C. This mutation disrupts the splicing of messenger RNA (mRNA), generating a gross abnormality in the processing of the luteinizing hormone beta-subunit mRNA, which abrogates the secretion of luteinizing hormone. We also determined that the female phenotype of this LHB mutation is characterized by normal pubertal development, secondary amenorrhea, and infertility.

1 June 2015 in Endocrine-Related Cancer
Verified
Journal Article
Open access
PDF file
ABAlbert Beckers
Albert Beckers
MLMaya Beth Lodish
Maya Beth Lodish
GTGiampaolo Trivellin
Giampaolo Trivellin
LRLiliya Rostomyan
Liliya Rostomyan
MLMisu Lee
Misu Lee
Constantine A. StratakisConstantine A. Stratakis
Constantine A. Stratakis
X-linked acrogigantism (X-LAG) is a new syndrome of pituitary gigantism, caused by microduplications on chromosome Xq26.3, encompassing the geneGPR101, which is highly upregulated in pituitary tumors. We conducted this study to explore the clinical, radiological, and hormonal phenotype and responses to therapy in patients with X-LAG syndrome. The study included 18 patients (13 sporadic) with X-LAG and microduplication of chromosome Xq26.3. All sporadic cases had unique duplications and the inheritance pattern in two families was dominant, with all Xq26.3 duplication carriers being affected. Patients began to grow rapidly as early as 2–3 months of age (median 12 months). At diagnosis (median delay 27 months), patients had a median height and weight standard deviation scores (SDS) of >+3.9 SDS. Apart from the increased overall body size, the children had acromegalic symptoms including acral enlargement and facial coarsening. More than a third of cases had increased appetite. Patients had marked hypersecretion of GH/IGF1 and usually prolactin, due to a pituitary macroadenoma or hyperplasia. Primary neurosurgical control was achieved with extensive anterior pituitary resection, but postoperative hypopituitarism was frequent. Control with somatostatin analogs was not readily achieved despite moderate to high levels of expression of somatostatin receptor subtype-2 in tumor tissue. Postoperative use of adjuvant pegvisomant resulted in control of IGF1 in all five cases where it was employed. X-LAG is a new infant-onset gigantism syndrome that has a severe clinical phenotype leading to challenging disease management.

1 October 2015 in Clinical Biochemistry
Verified
Journal Article
Open access
Gustavo Barcelos BarraGustavo Barcelos Barra
Gustavo Barcelos Barra
TRTiciane Henriques Santa Rita
Ticiane Henriques Santa Rita
JVJúlia de Almeida Vasques
Júlia de Almeida Vasques
CCCamilla Figueiredo Chianca
Camilla Figueiredo Chianca
LNLídia Freire Abdalla Nery
Lídia Freire Abdalla Nery
SCSandra Santana Soares Costa
Sandra Santana Soares Costa
The extracellular DNA occurring in plasma-EDTA and serum is a biomarker of growing interest, especially in prenatal diagnosis and oncology. The objectives of the present study were to compare the DNase activity in these specimens and to investigate its ex-vivo impact over the circulating cell-free DNA yield (ccfDNA), using the circulating cell-free fetal DNA (ccffDNA) as a tool. EDTA-plasma and serum from women bearing male fetus were submitted to an endogenous DNase activity assay based on qPCR hydrolysis probe degradation, they were treated with DNAse I to investigate the action of an exogenous nuclease and also submitted to different temperature conditions to investigate the temperature-dependent degradation of the ccffDNA. In all instances, all male ccffDNA were quantified by qPCR targeting the Y chromosome-specific sequence DYS-14. Moreover, a serial dilution of EDTA was added to nonanticoagulated plasma and serum before the endogenous DNAse activity assay, to investigate the EDTA-mediated inhibition of the blood's DNase. The endogenous nuclease activity was 14.9-fold higher in serum compared to EDTA-plasma. The DNAse I treatment did not alter the ccffDNA yields in EDTA-plasma, but completely degraded it in serum. The addition of increasing doses of EDTA to nonanticoagulated plasma and serum resulted in a stepwise inhibition of their nucleases activity. Finally, we observed a much more pronounced temperature-mediated decrease on the ccffDNA amount in serum compared to EDTA-plasma. The exogenous and endogenous DNases are more active in serum, the anticoagulant EDTA indirectly inhibits blood DNases, and consequently ccfDNA is protected from the blood's DNase preanalytical impact in EDTA-plasma.

1 August 2010 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MAMonalisa Ferreira Azevedo
Monalisa Ferreira Azevedo
Gustavo Barcelos BarraGustavo Barcelos Barra
Gustavo Barcelos Barra
LNLuciana Ansaneli Naves
Luciana Ansaneli Naves
LVLara Franciele Ribeiro Velasco
Lara Franciele Ribeiro Velasco
PCPatrícIa Godoy Garcia Castro
PatrícIa Godoy Garcia Castro
DADenis Reis de Assis
Denis Reis de Assis
Context: Selenoproteins are essential for life, and their biosynthesis requires the incorporation of the rare amino acid selenocysteine (Sec) in a process mediated by the Sec insertion sequence-binding protein 2 (SBP2). Although SBP2 is considered a rate-limiting factor mediating Sec incorporation, there has been little evidence so far linking SBP2 dysfunction to widespread selenoprotein-related disease. Objective: The objective of the study was to report the discovery of novel truncation mutations in the SBP2 gene (R120X/R770X) in a female adolescent and the clinical consequences of the combined deficiency of selenoproteins. Subjects and Methods: A 12-yr-old girl who presented with a syndrome of abnormal thyroid hormone metabolism, delayed bone maturation, congenital myopathy, and impaired mental and motor coordination development and her family were studied. The coding region of the SBP2 gene was analyzed by sequencing, and gel shift assays were performed to address the in vitro binding properties of the mutant SBP2 protein. Results: Serum levels of selenium and glutathione peroxidase in the proband were reduced, and selenoprotein P levels were undetectable. DNA sequencing of the SBP2 gene revealed a compound heterozygous mutation (R120X/R770X). The R120X mutation disrupted all functional motifs and the R770X inhibited the binding of SBP2 to Sec insertion sequence elements. Interestingly, selenium supplementation normalized serum selenium and glutathione peroxidase but not selenoprotein P levels and did not restore thyroid hormone metabolism dysfunction. Conclusions: This distinctive phenotype can only be explained by the combined deficiency of functionally important selenoproteins and pinpoints the clinical relevance of selenoproteins and selenium economy in human development.

1 February 2010 in Autoimmunity Reviews
Verified
Journal Article
Closed access
FRFrancieli de Sousa Rabelo
Francieli de Sousa Rabelo
LMLicia Maria Henrique da Mota
Licia Maria Henrique da Mota
RLRodrigo Aires Corrêa Lima
Rodrigo Aires Corrêa Lima
FLFrancisco Aires Corrêa Lima
Francisco Aires Corrêa Lima
Gustavo Barcelos BarraGustavo Barcelos Barra
Gustavo Barcelos Barra
AAAngélica Amorim Amato
Angélica Amorim Amato